Actelion is preparing for transformational growth to benefit all stakeholders, putting processes and infrastructure in place that will take its novel chemical entities currently in late-stage development through to become innovative medicines for patients.
| Date | Event | Description |
| 08 Feb | Bio CEO & Investor Conference | Actelion to present at the 12th Annual Bio CEO & Investor Conference |
| 18 Feb 2010 | FY Results 2009 | Actelion reports full year results for 2009 |
| 22 Apr 2010 | Q1 Results 2010 | Actelion reports its first quarter results for 2010 |
| 04 May 2010 | AGM 2010 | Annual General Meeting 2010 – update for stockholders on the progress made in 2009 |
| 22 Jul 2010 | HY Results 2010 | Webcast with financial results for the first 6 months of 2010 |
| 21 Oct 2010 | Q3 Results 2010 | Webcast with financial results for the first 9 months of 2010 |
Actelion presentations
- Actelion will present at the 12th Annual BIO CEO & Investor Conference on Monday, February 08 in New York, US. The presentation is scheduled for Monday, 8 February 2010 at 09.30 hrs ET (15.30 hrs Basel, CEST/ 14.30 UK, BST). The presentation will be available via webcast.
- Actelion presented at the J.P. Morgan Healthcare Conference in San Francisco, California on Monday, 11 January 2010. The webcast replay will be available here and ends and is accessible end of March.
| In CHF thousands results | Results 9M 2009 | Results 9M 2008 | in % | |
| Net revenues | 1,302,541 | 1,069,620 | 22 | |
| Operating expenses | 939,297 | 794,424 | 18 | |
| Operating income | 363,244 | 275,196 | 32 | |
| Cash EBIT | 462,008 | 355,643 | 30 | |
| Net income | 326,902 | 227,369 | 44 | |
| Diluted EPS in CHF | 2.66 | 1.84 | 45 | |
| No of shares in calculation | 122.743 m | 123.431 m | n/a |
